Osiris Therapeutics Inc
(NASDAQ: OSIR)
+0.67+6.32%Today's Close
|
11.27
unch
After hours
| Exchange: | NASDAQ |
| Stock: | Osiris Therapeutics Inc |
| Industry: | Biotechnology |
| Employees: | 59 |
| Osiris Therapeutics, Inc. (Osiris), is a stem cell therapeutic company. The Company focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. The Company operates in two business segments: Therapeutics and Biosurgery. The Company's Therapeutics business is focused on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Company's Biosurgery business, works to harness the ability of cells and novel constructs to promote the body's natural healing. In the Company's Biosurgery business, the Company manufactures , market and distributes Grafix and Ovation for tissue repair. In the Company's Therapeutics segment, its pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
